Effect of herbal medicine containing Zataria multiflora and Glycyrrhiza glabra on clinical and paraclinical symptoms in COVID-19

INTERVENTION: Intervention 1: In the intervention group, participants will receive herbal medicine(Zataria multiflora,Glycyrrhiza glabra) 6 drops every 3hours for 14 days. The control group will receive a placebo (no therapeutic value), resembled the herbal medicine with the same prescription. Both groups will receive routine treatments. Intervention 2: Control group: The control group will receive a placebo, resembled the herbal medicine tablets with the same prescription. Both groups will receive routine treatments. CONDITION: COVID‐19. ; COVID‐19, virus identified U07.1 PRIMARY OUTCOME: ESR (Erythrocyte Sedimentation Rate). Timepoint: Before intervention and 14 days after intervention. Method of measurement: Checking the sedimentation rate of erythrocytes in a special tube within one hour. Mortality. Timepoint: Daily. Method of measurement: Questionnaire. Number of hospitalization days. Timepoint: After intervention. Method of measurement: Questionnaire. Oxygen saturation (SpO2). Timepoint: Daily. Method of measurement: Pulse Oximeter. Respiratory Rate. Timepoint: Daily. Method of measurement: Observation. Serum CRP level. Timepoint: Before intervention and 14 days after intervention. Method of measurement: Biochemical method. Serum White Blood Cell count. Timepoint: Before intervention and 14 days after intervention. Method of measurement: Laboratory cell counter. SECONDARY OUTCOME: The end time of dry Cough. Timepoint: Daily. Method of measurement: ?Daily symptom recording questionnaire. The time of recovery from difficulty in breathing or shortness of breath. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire. The time of recovery of temperature equal to or grater than 37.8 C. Timepoint: Daily. Method of measurement: Daily symptom recording questionnaire. INCLUSION CRITERIA: Having definite COVID‐19 disease and get hospitalized Both sexes Age over 15 years Obtaining informed consent to participate in the trial Non‐participation in another clinical trial simultaneously Patients admitted to ICU